Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
ALS Data For Verdiperstat Expected In 2022
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
